Gain Therapeutics (GANX) Debt Ratio (2020 - 2026)

Gain Therapeutics' Debt Ratio history runs 7 years deep, the most recent figure standing at 0.02 for Q1 2026.

• In Q1 2026, Debt Ratio fell 45.81% year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (down 45.81% YoY), while the FY2025 annual figure was 0.02, down 51.42% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.02, up from 0.02 in the prior quarter.
• The five-year high for Debt Ratio was 0.05 in Q2 2025, with the low at 0.02 in Q1 2022.
• The 5-year median for Debt Ratio is 0.03 (2023), against an average of 0.03.
• The sharpest annual moves came in 2023 and 2025: Debt Ratio surged 86.83% in 2023, then tumbled 51.42% in 2025.
• Gain Therapeutics' Debt Ratio stood at 0.03 in 2022, then advanced by 21.87% to 0.03 in 2023, then increased by 18.53% to 0.04 in 2024, then sank by 51.42% to 0.02 in 2025, then advanced by 13.45% to 0.02 in 2026.
• Business Quant data shows GANX's Debt Ratio at 0.02 in Q1 2026, 0.02 in Q4 2025, and 0.04 in Q3 2025.